Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1065-1071

  Veronesi, Umberto ^a   Mariani, L ^b   Decensi, A ^a,c   Formelli, F ^b   Camerini, T ^b   Miceli, R ^b   Di Mauro, M G ^b   Costa, A ^d   Marubini, E ^e   Sporn, M B ^f   De Palo, G ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d IRCCS   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Breast neoplasms; Chemoprevention; Clinical trial; Fenretinide

Indexed keywords

FENRETINIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; METASTASIS; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 33745613818     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl047     Document Type: Article

References (36)

1. Sporn MB. Carcinogenesis and cancer: Different perspectives on the same disease. Cancer Res 1991; 51: 6215-6218.
2. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res 2002; 62: 5119-25.
3. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000; 130(2S Suppl): S479-S482.
4. Decensi A, Serrano D, Bonanni B et al. Breast cancer prevention trials using retinoids. J Mammary Gland Biol Neoplasia 2003; 8: 19-30.
5. Moon RC, Thompson HJ, Becci PJ et al. N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979; 39: 1339-1346.
6. Mehta RG, Moon RC, Hawthorne M et al. Distribution of fenretinide in the mammary gland of breast cancer patient. Eur J Cancer 1991; 27: 138-141.
7. Formelli F, Clerici M, Campa T et al. Five year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentration. J Clin Oncol 1993; 11: 2036-2042.
8. Lotan R. Retinoids and apoptosis: Implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655-1657.
9. Costa A, Formelli F, Chiesa F et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 1994; 54: S2032-2037.
10. Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999; 91: 1847-1856.
11. Hankley BF, Curtis RE, Naughton MD et al. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the efficacy of the radiation therapy. J Natl Cancer Inst 1983; 70: 797-804.
12. Broet P, de la Rochefordiere A, Scholl SM et al. Contralateral breast cancer: Annual incidence and risk parameters. J Clin Oncol 1995; 13: 1578-1583.
13. Formelli F, Carsana R, Costa A et al. Plasma retinol level reduction by the synthetic retinoid fenretinide: A one year follow up study of breast cancer patients. Cancer Res 1989; 49: 6149-6152.
14. De Palo G, Camerini T, Marubini E et al. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 1997; 83: 884-893.
15. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
16. Torrisi R, Pensa F, Orengo MA et al. The synthetic retinoid fenretinide lowers plasma insulin-like factor I levels in breast cancer patients. Cancer Res 1993; 53: 4769-4771.
17. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551-61.
18. De Palo G, Mariani L, Camerini T et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002; 86: 24-27.
19. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998; 90: 1371-1388.
20. Decensi A, Veronesi U, Miceli R et al. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 2003; 9: 2032-2039.
21. Sivaraman L, Stephens LC, Markaverich BM et al. Hormone-induced refractoriness to mammary carcinogenesis in Wistar-Furth rats. Carcinogenesis 1998; 19: 1573-81.
22. Sivaraman L, Conneely OM, Medina D et al. p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci USA 2001; 98: 12379-84.
23. Tu Y, Jerry DJ, Pazik B et al. Sensitivity to DNA damage is a common component of hormone-based strategies for protection of the mammary gland. Mol Cancer Res 2005; 8: 435-42.
24. Welsch CW, DeHoog JV, Moon RC. Inhibition of mammary tumorigenesis in nulliparous C3H mice by chronic feeding of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide. Carcinogenesis 1983; 4: 1185-1187.
25. McCormick DL, Moon RC. Influence of delayed administration of retinyl acetate on mammary carcinogenesis. Cancer Res 1982; 42: 2639-2643.
26. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004; 12: 1475-84.
27. Sabichi AL, Modiano MR, Lee JJ et al. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res 2003; 9: 2400-5.
28. Rodriguez-Burford C, Steele VE, Anderson AS et al. Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology. Nutr Cancer 2002; 43: 67-75.
29. Pellegrini R, Mariotti A, Tagliabue E et al. Modulation of markers associated with tumor aggressiveness in human breast cancer cell lines by N-(4-hydroxyphenyl) retinamide. Cell Growth Differ 1995; 6: 863-869.
30. Menard S, Camerini T, Mariani L et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 2001; 93: 240-1.
31. Guerrieri-Gonzaga A, Robertson C, Bonanni B et al. Preliminary results on safety and activity of a randomized double-blind 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006; 24: 129-135.
32. Simeone AM, Deng CX, Kelloff GJ et al. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells. Carcinogenesis 2005; 26: 1000-7.
33. Camerini T, Mariani L, De Palo G et al. Safety of the Synthetic Retinoid Fenretinide: Long-Term Results From a Controlled Clinical Trial for the Prevention of Contralateral Breast Cancer. J Clin Oncol 2001; 19: 1664-1670.
34. Turton JA, Willars GB, Haselden JN et al. Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol 1992; 73: 551-63.
35. Kenel MF, Krayer JH, Merz EA et al. Teratogenicity of N-(4-hydroxyphenyl)-all-trans-retinamide in rats and rabbits. Teratog Carcinog Mutagen 1988; 8: 1-11.
36. Formelli F, De Palo G, Costa A et al. Human transplacental passage of the retinoid fenretinide (4HPR). Eur J Cancer 1998; 34: 428-9.